Professors Marc Fisher and Liping Liu discuss the CHANCE and PRINCE clinical trials focusing on their backgrounds and key results, and commenting on their clinical implications.

This programme is made possible thanks to an independent educational grant from AstraZeneca.

Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/

Professor Marc Fisher and Dr Greg Albers discuss the POINT trial, also commenting on when to consider ticagrelor versus clopidogrel.

This programme is made possible thanks to an independent educational grant from AstraZeneca.

Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/

Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.

This programme is made possible thanks to an independent educational grant from AstraZeneca.

Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/